Suppr超能文献

展示弗林蛋白酶抗原的实验性病毒样颗粒疫苗可引发自身抗体的产生,并且在小鼠中耐受性良好。

Experimental VLP vaccine displaying a furin antigen elicits production of autoantibodies and is well tolerated in mice.

作者信息

Lampinen Vili, Ojanen Markus J T, Caro Fernanda Muñoz, Gröhn Stina, Hankaniemi Minna M, Pesu Marko, Hytönen Vesa P

机构信息

Faculty of Medicine and Health Technology, Tampere University Tampere Finland

Fimlab Laboratories Ltd FI-33014 Tampere Finland.

出版信息

Nanoscale Adv. 2024 Oct 9;6(24):6239-52. doi: 10.1039/d4na00483c.

Abstract

Proprotein convertase (PCSK) enzymes serve a wide range of regulatory roles in mammals, for example in metabolism and immunity, and altered activity of PCSKs is associated with disorders, such as cardiovascular disease and cancer. Inhibition of PCSK9 activity with therapeutic antibodies or small interfering RNAs is used in the clinic to lower blood cholesterol, and RNA interference -based silencing of () is being evaluated in clinical trials as a cancer treatment. Inhibiting these proteins through vaccine-induced autoantibodies could be a patient-friendly way to reduce the frequency of intervention and the overall price of treatment. Here, we show that a self-directed immune response against PCSK9 and furin can be generated in mice by presenting fragments of the proteins on norovirus-like particles (noro-VLPs). We genetically fused three PCSK peptides and the P domain of furin to the SpyCatcher linker protein and covalently conjugated them on noro-VLPs SpyCatcher/SpyTag linkage. Both PCSK9 peptides and the furin P domain generated antigen specific IgGs even without conventional adjuvants. Importantly, vaccinating against furin did not cause adverse events or immune-mediated inflammatory disease. This study adds further support for the feasibility of VLP-based anti-PCSK9 vaccines and shows that the same principles can be applied to make novel vaccine candidates against other endogenous proteins such as furin. We also demonstrate that the noro-VLP can be used as a vaccine platform for presenting self-antigens.

摘要

前蛋白转化酶(PCSK)在哺乳动物中发挥着广泛的调节作用,例如在新陈代谢和免疫方面,PCSK活性的改变与心血管疾病和癌症等疾病有关。在临床上,使用治疗性抗体或小干扰RNA抑制PCSK9活性来降低血液胆固醇,基于RNA干扰的()沉默作为一种癌症治疗方法正在临床试验中进行评估。通过疫苗诱导的自身抗体抑制这些蛋白质可能是一种对患者友好的方式,可以减少干预频率和治疗的总体费用。在这里,我们表明,通过在诺如病毒样颗粒(诺如-VLPs)上展示蛋白质片段,可以在小鼠体内产生针对PCSK9和弗林蛋白酶的自身免疫反应。我们将三种PCSK肽和弗林蛋白酶的P结构域基因融合到SpyCatcher连接蛋白上,并通过SpyCatcher/SpyTag连接将它们共价偶联到诺如-VLPs上。即使没有传统佐剂,PCSK9肽和弗林蛋白酶P结构域也能产生抗原特异性IgG。重要的是,针对弗林蛋白酶接种疫苗不会引起不良事件或免疫介导的炎症性疾病。这项研究进一步支持了基于VLP的抗PCSK9疫苗的可行性,并表明相同的原理可以应用于制备针对其他内源性蛋白质(如弗林蛋白酶)的新型候选疫苗。我们还证明,诺如-VLP可以用作呈现自身抗原的疫苗平台。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a792/11614056/3d4016197273/d4na00483c-f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验